Skip to main content
. 2015 Oct 19;6(39):41736–41749. doi: 10.18632/oncotarget.6153

Figure 2. Effect of GSK2141795 either alone or in combination with cisplatin on the viability, cell cycle and tumor growth of SKOV3 cells.

Figure 2

SKOV3 cells were exposed to a range of GSK2141795 concentrations (0.075 - 10 μM) either as a single agent or in combination with cisplatin (cddp; 25 μM) for 72 hours, when cell viability was measured using MTT A. Cell cycle analysis of SKOV3 cells following treatment with GSK2141795 as a single agent (5 μM) or in combination with cisplatin (25 μM) for 24 hours B. SKOV3 tumour-bearing mice were dosed daily with GSK2141795 (30 mg/Kg; oral) or vehicle ± biweekly cisplatin (1.5 mg/Kg; intraperitonal) for 14 days C.. Data shown in A. and B. are the means ± SEM of 3-4 experiments performed in triplicate, and in C. the mean ± SEM for n = 8 tumours/treatment, *p < 0.05, **p < 0.01, ***p < 0.001 (paired t-test), where the symbols *, # and + represent significant differences when compared to vehicle, cisplatin and GSK2141795 data at 14 days, respectively.